Abstracts tagged "hypertension and steroids"

Abstract Number: 2361 • 2017 ACR/ARHP Annual Meeting
Associated Factors of Hypertension and Hyperglycemia Related to Steroid Pulse in Autoimmune Diseases
Eduardo Saul Acevedo-Castañeda¹, Marco Ulises Martinez-Martinez², David Herrera Van Oostdam³, Carlos Abud-Mendoza⁴, Homero López-Ferretis⁵, Angel Javier Pedro Martínez⁵, Dolores Ramos-Bello⁶, Tania Adriana Luna-Zúñiga⁵, Georgina Aguilera Barragán-Pickens⁵ and Georgina Martínez-Flores⁵, ¹Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ²Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ³Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ⁵Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁶Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico
-Background/Purpose: Steroid pulses are widely used in treatment for multiple inflammatory pathologies. The prevalence of hyperglycemia is 55-98%, and hypertension 5-52.5%. (1-2); safety profile could…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].